The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

Garcia and colleagues investigated plasma lipid levels and lipodystrophy incidence in patients with early HIV disease who had received one year of a dual or triple antiretroviral regimen. Patients were randomized to one of the following treatment arms:

EARTH-1 (n) EARTH-2 (n)
AZT + ddC (29) AZT + 3TC (28)
AZT + ddI (32) d4T + 3TC (34)
d4T + ddI (33) d4T + 3TC + IDV (32)
d4T + 3TC + RTV (33) No treatment (34)

Only the d4T + 3TC + ritonavir (RTV) treatment arm showed changes in laboratory parameters, with increases in cholesterol and triglycerides. One patient in the group had a cholesterol level above normal, while the percentage of patients with abnormal triglycerides increased from 23% at baseline to 62% at follow up. Lipodystrophy was uncommon in the study; it was observed in only one patient receiving dual therapy and one patient receiving triple therapy.

The data suggest that disease state or length of infection may be associated with clinical lipodystrophy. It also indicates that RTV use may be involved in the elevation of triglycerides and cholesterol.

Abstract: Incidence of Metabolic Changes and Lipodystrophy in Two Trials Comparing Double Versus Triple Antiretroviral Therapy in Early HIV Disease
Authored by: F. Garcia, M. Ortega, A. Cruceta, C. Tortajada, A. Soriano, L. Zamora, J.M. Miro, T. Pumarola and J.M. Gatell for the Spanish EARTH Studies

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.